Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes Vaccine | Zendy

David I. Bernstein | Zendy; F. Y. Aoki | Zendy; S K Tyring | Zendy; Lawrence R. Stanberry | Zendy; C. S. Pierre | Zendy; Stephen D. Shafran | Zendy; Geert Leroux Roels | Zendy; Koen Van Herck | Zendy; Anne Bollaerts | Zendy; Gary Dubin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes Vaccine

Author(s) -

David I. Bernstein,

F. Y. Aoki,

S K Tyring,

Lawrence R. Stanberry,

C. S. Pierre,

Stephen D. Shafran,

Geert Leroux Roels,

Koen Van Herck,

Anne Bollaerts,

Gary Dubin

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/429240

Subject(s) - medicine , immunogenicity , vaccination , placebo , adjuvant , immunology , immunity , antibody titer , virology , antibody , titer , immune system , alternative medicine , pathology

Two previous trials have suggested that a herpes simplex virus (HSV) type 2 glycoprotein D (gD) vaccine combined with the adjuvants alum and 3'-O-deacylated-monophosphoryl lipid A (MPL) is well tolerated and provides protection against genital herpes disease in women with no preexisting HSV antibody.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research